Skip to main content
. 2020 Jan 20;2020(1):CD011628. doi: 10.1002/14651858.CD011628.pub2

Comparison 12. Secukinumab vs placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Proportion of participants with adverse effects in the short term 1 157 Risk Ratio (M‐H, Random, 95% CI) 3.29 [1.40, 7.75]
2 Proportion of participants achieving a 50% reduction in disease severity in the short term 1 157 Risk Ratio (M‐H, Random, 95% CI) 1.55 [1.02, 2.35]